Outcomes of long-term maintenance infliximab therapy in adult patients with moderate to severe Crohn's disease from March 2003 to December 2010: A single centre experience

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F12%3A10125932" target="_blank" >RIV/00216208:11320/12:10125932 - isvavai.cz</a>
Result on the web
<a href="http://www.remedia.cz/Archiv-rocniku/Rocnik-2012/3-2012/Outcomes-of-long-term-maintenance-infliximab-therapy-in-adult-patients-with-moderate-to-severe-Crohn-s-disease-from-March-2003-to-December-2010/e-1dQ-1gv-1h5.magarticle.aspx" target="_blank" >http://www.remedia.cz/Archiv-rocniku/Rocnik-2012/3-2012/Outcomes-of-long-term-maintenance-infliximab-therapy-in-adult-patients-with-moderate-to-severe-Crohn-s-disease-from-March-2003-to-December-2010/e-1dQ-1gv-1h5.magarticle.aspx</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Outcomes of long-term maintenance infliximab therapy in adult patients with moderate to severe Crohn's disease from March 2003 to December 2010: A single centre experience
Original language description
We evaluated the long-term clinical benefit of infliximab (IFX) in a total of 74 patients with moderate to severe Crohn's disease (CD); the median follow-up was 16 months (interquartile range 13-35). Methods: We compared the quality of mucosal healing (MH) in 3 groups of patients with CD. Group I (GI): CD duration < 3 years, treated with IFX. Group II (GII): CD duration > 3 years, treated with IFX. Group III (GIII): CD duration > 3 years, treated with IFX + azathioprine (AZA). Results: At week 52, deepclinical remission was observed in seven of 21 patients in GI (33.33%), in three of 19 patients in GII (15.70%), and in eight of 20 patients in GIII (40.00%). The differences among groups were statistically significant in the likelihood ratio test (P = 0.019) and logrank test (P = 0.042). The covariate analysis showed significant differences in the outcomes between GIII and GII (OR 7.20, P = 0.05) and between GI and GII (OR 6.3, P = 0.052), and a nonsignificant difference between GIII an
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FJ - Surgery including transplantology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)